Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites. WHO Network for HIV Isolation and Characterization.
Serologic reactivities of serum or plasma from 55 HIV-1 subjects in four countries--Brazil, Rwanda, Thailand, and Uganda--were examined by V3 peptide immunoassay. Forty-seven (85.5%) of the 55 specimens tested positive to the homologous peptide. A strong correlation between serotype (i.e., pattern of serologic reactivity with a panel of peptides) and genotype was not found. However, the V3 peptide immunoassays may be useful for epidemiologic studies to trace the distinctive HIV-1 strains from different geographic regions of the world. The serology data obtained may be useful for the development of effective V3-based vaccines.
Pau
C P
CP
Division of HIV/AIDS, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia 30333.
Kai
M
M
Holloman-Candal
D L
DL
Luo
C C
CC
Kalish
M L
ML
Schochetman
G
G
Byers
B
B
George
J R
JR
D016915:AIDS Vaccines / Q000494:pharmacology; D000595:Amino Acid Sequence; D000940:Antigenic Variation; D001938:Brazil / Q000453:epidemiology; D016000:Cluster Analysis; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000821:virology; D015497:HIV-1 / Q000145:classification / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology; D010455:Peptides / Q000235:genetics / Q000276:immunology; D012432:Rwanda / Q000453:epidemiology; D016036:Seroepidemiologic Studies; D012703:Serotyping; D013785:Thailand / Q000453:epidemiology; D014454:Uganda / Q000453:epidemiology; D014944:World Health Organization
D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D010455:Peptides